Levetiracetam Treatment of Tardive Dyskinesia

This study has been completed.
UCB, Inc.
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
First received: February 10, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Condition Intervention Phase
Tardive Dyskinesia
Drug: levetiracetam
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • AIMS total score


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none


  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00291213

United States, Connecticut
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
UCB, Inc.
Principal Investigator: Scott W Woods, MD Yale School of Medicine
  More Information

No publications provided by Yale University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00291213     History of Changes
Other Study ID Numbers: YaleHIC26585
Study First Received: February 10, 2006
Last Updated: February 10, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 16, 2014